AltPep

📍 Seattle, United States🗓 Founded 2019👥 35 employees💰 Last funded 2021
Biotechnology🌐 altpep.com
Website LinkedIn
AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach. Our lead program aims to identify Alzheimer’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in AltPep?
AltPep has 2 investors on record on gritt.io, including 2 early-stage backers.
When did AltPep last raise funding?
The most recent investment in AltPep recorded on gritt.io was in 2021.
When was AltPep founded?
AltPep was founded in 2019.
What industry is AltPep in?
AltPep operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is AltPep based?
AltPep is headquartered in Seattle, United States.